Treatment of ulcerative colitis with adalimumab or infliximab: Long-term follow-up of a single-centre cohort

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 4, 2010, Pages 522-528

  Gies, N ^a   Kroeker, K I ^a   Wong, K ^a   Fedorak, R N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; COLON RESECTION; CORTICOSTEROID THERAPY; DEFECATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG INFUSION REACTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; INTESTINE FUNCTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; OUTPATIENTS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77954752112     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04380.x     Document Type: Article

References (17)

1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353:2462 2476. (Pubitemid 41770166)
2. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. J Crohn's Colitis 2010 4:S5 6.
3. Hinojosa J, Gomollón F, García S, et al. Efficacy and safety of short-term Adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007 25:409 418.
4. Teshima CW, Thompson A, Dhanoa L, et al. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009 23:348 352.
5. Chowers Y, Allez M. Efficacy of anti-TNF in Crohn's disease: how does it work? Curr Drug Targets 2010 11:138 142.
6. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000 118:S2 8.
7. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 96:2929 2933.
8. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114:39 43.
9. Afif W, Leighton JA, Hanauer SB, et al. Open-label study of Adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009 15:1302 1307.
10. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or response to infliximab: an open-label study. World J Gastroenterol 2007 13:2328 2332. (Pubitemid 46860734)
11. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008 28:966 972.
12. Hudis N, Rajca B, Polyak S, et al. The outcome of active ulcerative colitis treated with adalimumab. Gastroenterology 2009 136:A-683.
13. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008 2:219 225.
14. Senent S, Martín-Arranz M, Merino L, et al. Infliximab in ulcerative colitis: concomitant cytomegalovirus infection, Lifes Quality, PPD positive have an influence on the treatment with infliximab. Gastroenterology 2009 136:A-682.
15. Jürgens M, Brand S, Laubender R, et al. Disease activity and pANCA status determine early response to infliximab in ulcerative colitis. Gastroenterology 2009 136:A-680.
16. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009 30:210 226.
17. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009 137:1250 1260.